MedPath

Prevention of oral mucositis in pediatric patients with acute lymphoblastic leukemia undergoing chemotherapy: a randomized controlled, cross-over trial using 0.12% chlorhexidine gluconate and 1% povidone iodine mouthwash

Phase 4
Recruiting
Conditions
oral mucositis
leukemia
Cancer - Children's - Leukaemia & Lymphoma
Oral and Gastrointestinal - Inflammatory bowel disease
Registration Number
ACTRN12614000158662
Lead Sponsor
Amanda Christina C. Dujua, MD
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Children ages of 6 to 18 years old diagnosed with Acute Lymphoblastic Leukemia who are undergoing Induction, Consolidation, or Re-induction chemotherapy (based on the Modified Berlin-Frankfurt-Munster Acute Lymphoblastic Leukemia Protocol) or Induction or Intensification chemotherapy (based on the Children’s Cancer Group Protocol, CCG-1941: Bone Marrow Transplantation versus Prolonged Intensive Chemotherapy for Children with Acute Lymphoblastic Leukemia after an Initial Bone Marrow Relapse) and seeking consult at STUH-BCI, and are capable of tooth-brushing and mouth-rinsing as judged by the principal investigator

Exclusion Criteria

Children with oral mucositis or any oral lesion at initial assessment.
Children with the following conditions: hypersensitivity to iodine, hyperthyroidism, mental retardation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
determining whether there is a difference in effect of 0.12% chlorhexidine and 1% povidone iodine mouthrinses that are both accepted as standard of care for oral mucositis in pediatric cancer patients using the Oral Mucositis Assessment Scale and World Health Organization Grading Scale[2 weeks]
Secondary Outcome Measures
NameTimeMethod
Decrease in severity of oral mucositis, using the Oral Mucositis Assessment Scale and World Health Organization Grading Scale[2 weeks]
© Copyright 2025. All Rights Reserved by MedPath